You are here: Industry Insights > Market News > US company claims Irish firm Amgen infringing cancer drug patent

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

HUMIDIFIER FILTER

Oil fume adsorption filter

US company claims Irish firm Amgen infringing cancer drug patent

firstwordpharmaMarch 12, 2019

Tag: Roche , Irish firm , cancer drug patent

Favorites

Roche's Genentech unit has filed a lawsuit in the US accusing Amgen of infringing a patent covering the cancer drug Avastin, Irish Examiner reported Monday.
Genentech said it has received a notice from the FDA that Amgen plans to launch its biosimilar, named Mvasi, in Ireland.
In seeking an injunction, Genentech argued that it will suffer substantial damage if Amgen is permitted to launch its therapy.
Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

Previous:Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Next:Oncoceutics licenses rights for its anti-cancer compound to Ohara

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

US company claims Irish firm Amgen infringing cancer drug patent | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Chromium-free Electrochemical Polishing Reagent for Stainless Steel

Chromium-free Electrochemical Polishing Reagent for Stainless Iron

Specialty & agrochemical, pharma, Fertilizers and Biological Vacuum Belt Dryer Machine

Diagnostics for Oil, Gas and Petrochemicals Industries

Electrochemical Passivating Equipment

Electrochemical Polishing Automated Production Lines

Electrochemical Polishing Equipment of Continuous Processing

Chromium-free Electrochemical Polishing Reagent for Nickel Alloy

Electrochemical Processing Machine Of Inner Tube

Electrochemical Polishing, Cleaning and Drying Equipment for Vacuum Insulation Cup Of Stainless Stee

US company claims Irish firm Amgen infringing cancer drug patent

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>